Biotronik trial milestones
This article was originally published in The Gray Sheet
Biotronik enrolls the first patient July 23 in its 1,750-patient REPLACE registry, the first and largest prospective trial focusing on complications associated with replacements and system upgrades of FDA-approved implantable pacemakers and defibrillators. The registry will be conducted in 75 to 100 U.S. centers and will include all manufacturers' models. Also on July 23, Biotronik completed enrollment in its 1,000-patient TRUST study. The randomized, prospective trial is evaluating if patients with Lumos and Lumax VT-T/DR-T defibrillators followed by Biotronik's Home Monitoring and IEGM Online remote monitoring technology have outcomes at least equivalent to those receiving standard in-person follow up...
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.